LAUSANNE, Switzerland, September 13, 2017 /PRNewswire/ --
The Journal of American Academy of Dermatology, recently issued "the Efficacy of Autologous platelet-rich plasma combined with hyaluronic acid on skin facial rejuvenation: A prospective study" by Hersant B, SidAhmed-Mezi M, Niddam J, La Padula S, Noel W, Ezzedine K, Rodriguez AM, Meningaud JP. (http://www.jaad.org/article/S0190-9622(17)31769-3/pdf )
(Logo: http://mma.prnewswire.com/media/555148/Regen_Lab_Logo.jpg )
Through published clinical studies, Cellular Matrix technology has also gained acceptance in the field of Musculoskeletal Pain Management, in particular for the treatment of Knee Osteoarthritis.
- For the preparation of Platelet Rich Plasma in tubes with a thixotropic separator gel: U.S. patent US8529957, European patent EP2073862B, (...)
- On the CellularMatrix Technology, for the preparation of Platelet Rich Plasma mixed with Hyaluronic Acid in tubes: U.S. patent US8945537, U.S. patent US9517255, European patent EP2544697B1, Canada, PR. China, Australia, Japan, Russia, Israel, (...)
Regen Lab seeks to enforce its intellectual property and patent rights worldwide. It has already filed numerous patent lawsuits in Europe, PR of China and the United Stated of America (http://www.prweb.com/releases/2016/11/prweb13849507.htm).
Regen Lab will be participating in the EADV European Academy of Dermatology 2017 Annual Meeting in Geneva, Switzerland, September 13-17 and the AAD American Academy of Dermatology 2018 Annual Meeting in San Diego, February 16-20.
Additional information about RegenLab, its intellectual property and related actions can be found at http://www.regenlab.com/patents .
CONTACT: David Cohen, firstname.lastname@example.org, +41-21-864-01-11